Glucagon-like peptide-1

An incretin hormone that plays a crucial role in glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and promoting satiety. It serves as the basis for several therapeutic agents used in the treatment of type 2 diabetes and obesity, differentiating itself by its multifaceted approach to managing blood sugar levels and weight. The primary beneficiaries of GLP-1 therapies are individuals with type 2 diabetes and those struggling with obesity.

Glucagon-like peptide-1 was discovered on April 26th 2023 and it currently has a search volume of 550K with a growth of +900%.